Dr. Anker is broad certified in Neurological Surgery with a focus in a
variety of conditions including disorders of the nervous system, Laminectomy,
Glioblastoma, and spinal disc herniation, just to name a few. He is an
active member in several societies including American Association of Neurological
Suregons, California Association of Neurological Surgeons, and Society
of Neuro-Oncology; just to name a few.
Dr. Anker has the best bedside manner with his patients and their families.
He treats all his staff with respect and grace and is a great team leader.
He is highly intelligent, driven, yet humble and easily connects with
staff and patients. He is a leader that exhibits all the qualities of
dignity and excellence. He frequently receives acts of appreciation from
his patients, their families and his peers.
He was the first physician to initiate a complex vaccine study at two St.
Joseph Health Ministries with the St. Joseph Health System Cancer Consortium.
Dr. Anker also participates in The Cancer Prevention and treatment Biospecimen
Repository Protocol in 2010; Phase III Radnomized Trial of the Role of
Whole Vrain Radiation Therapy in Addition to Radiosurgery in Patients
with One to Three Cerebral Metastases also in 2010; Phase II double blinded
placebo controlled study of Bevacizumab with or without AMG 386 in patients
with recurrent Gliboblastoma or Gliosarcomma in 2013; and Phase III clinical
trial evaluating DVC ax@-L, autologus dendtritic cells (DC) pulsed with
tumor lysate antigen for the treatment of Glioblastoma Multiforme (GMB) in 2012.
In 2013, he started Phase I/II Trial of Concurrent RAD001 (Everolimus)
with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in
Newly Diagnosed Glioblastoma. In 2014, Dr. Ankers also Expanded Access
Protocol for the Treatment of Glioblastoma Multiforme in Patients with
Already Manufactured DCVax-L, Autologous Dendritic Cells Pulsed with Tumor
Lysate Antigen Who Have Screen-Failed Protocol 020221; Phase I/Comparative
Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab
in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme.